Telehealth Ketamine for Depression

Depression is the primary condition for which telehealth ketamine is sought and prescribed. The evidence base for ketamine's antidepressant effects is robust, and the telehealth model has made this treatment accessible to patients who would otherwise be unable to access it. This guide covers the evidence, candidacy criteria, and how to access telehealth ketamine for depression.

The Evidence for Ketamine in Depression

Mechanism of Action

Ketamine's antidepressant mechanism differs fundamentally from traditional antidepressants. While SSRIs and SNRIs target serotonin and norepinephrine systems over weeks, ketamine acts rapidly on the glutamate system—specifically as an NMDA receptor antagonist. This produces rapid synaptic changes and a surge in BDNF (brain-derived neurotrophic factor), a protein associated with neuroplasticity and new neural connection formation.

The result is an antidepressant effect that can onset within hours of treatment—a speed unprecedented in psychiatric pharmacology.

Clinical Evidence

The clinical evidence for ketamine in depression is substantial:

• Multiple randomized controlled trials have demonstrated ketamine's superiority over placebo for treatment-resistant depression (TRD)
• Response rates in TRD populations range from 50-70% in controlled studies
• Remission rates are lower but clinically meaningful (25-35%)
• The antidepressant effect is typically time-limited without maintenance treatment
• The FDA's approval of esketamine (Spravato) for treatment-resistant depression and major depressive disorder with suicidal ideation reflects the strength of this evidence

For treatment-resistant depression—defined as failure of at least two adequate antidepressant trials—ketamine is increasingly considered a standard treatment option rather than an experimental one.

Who Qualifies for Telehealth Ketamine for Depression?

Psychiatric Criteria

Most telehealth ketamine platforms require:

• A diagnosis of major depressive disorder (MDD) or another depressive disorder
• Documented history of treatment with at least one (often two) antidepressants without adequate response
• Psychiatric stability—no acute suicidal crisis, no recent hospitalization, ability to participate safely in at-home treatment (see our patient selection guide for full criteria)

Severity Considerations

Telehealth ketamine is most appropriate for moderate to moderately severe depression. Patients with severe depression, particularly with acute suicidal ideation or psychomotor retardation severe enough to impair self-care, are better served by in-person treatment with closer monitoring.

Most platforms administer the PHQ-9 (a validated 9-item depression scale) at intake. Scores in the moderate range (10-19) are typically acceptable for the at-home model. Very high scores (≥20) may warrant more intensive initial evaluation.

Medical Exclusions

Patients with the following should not receive ketamine without special consideration:

• Uncontrolled hypertension or significant cardiovascular disease
• Active liver disease (ketamine is metabolized by the liver)
• History of psychosis or schizophrenia
• Active alcohol use disorder (ketamine combined with alcohol is dangerous; chronic heavy use affects ketamine metabolism)
• Pregnancy

Response and Outcomes

What to Expect

Patients who respond to ketamine for depression often notice effects within 24-72 hours of the first treatment. For a detailed walkthrough of the treatment experience, see what to expect from telehealth ketamine therapy. Common reports include:

• Increased motivation and energy
• Improved ability to feel positive emotions (what psychiatrists call "brightening of affect")
• Reduced rumination and negative thought spiraling
• Improved sleep quality

Not every patient responds. Non-response to an initial course does not necessarily mean ketamine will not work—dose adjustment, formulation change, or transition to IV ketamine may produce response in some patients who do not respond to sublingual protocols.

Durability

The antidepressant effect of ketamine is not permanent without continued treatment. After an initial course, effects typically last weeks to months before requiring maintenance. The integration work done between and after sessions appears to contribute to durability—patients who actively engage with psychotherapy and behavioral changes during the ketamine window tend to sustain benefit longer.

Platforms That Treat Depression

All major telehealth ketamine platforms list depression as a primary indication. Depression is the most common reason patients seek telehealth ketamine, and all established platforms have experience treating it.

What to Tell Your Provider

When pursuing telehealth ketamine for depression, provide:

• Your formal diagnosis (if one has been given) and the date of onset
• The antidepressants you have tried, the doses, and why they were discontinued
• Your current depression severity (the PHQ-9 questionnaire will be used, but your narrative is valuable)
• Whether you are currently in therapy, and if so, your therapist's contact information
• Any history of mood cycling or hypomanic episodes (important for bipolar screening)

If You Are Currently on Antidepressants

Many patients receive ketamine while continuing their existing antidepressants. Most antidepressants are compatible with ketamine. The significant exception: MAO inhibitors (MAOIs) should not be combined with ketamine—they require a washout period before starting ketamine therapy. Discuss all medications with your provider.

Integrating Ketamine into a Depression Treatment Plan

Ketamine works best as part of a comprehensive treatment approach, not as a standalone intervention. Patients who combine ketamine with:

• Active psychotherapy (particularly CBT, ACT, or psychodynamic therapy)
• Regular physical activity
• Healthy sleep practices
• Reduced alcohol use
• Social engagement

...tend to sustain their improvements longer and require less frequent maintenance dosing. The neuroplastic window that ketamine opens is an opportunity—the therapeutic work done during that window is what translates the chemical change into a life change.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches